Federal health authorities recommend pause of Johnson & Johnson vaccine after 6 rare, severe blood clots

The Centers for Disease Control and Prevention and U.S. Food and Drug Administration recommended health providers pause distribution of the Johnson & Johnson vaccine April 13. (Olivia Aldridge/Community Impact Newspaper)
The Centers for Disease Control and Prevention and U.S. Food and Drug Administration recommended health providers pause distribution of the Johnson & Johnson vaccine April 13. (Olivia Aldridge/Community Impact Newspaper)

The Centers for Disease Control and Prevention and U.S. Food and Drug Administration recommended health providers pause distribution of the Johnson & Johnson vaccine April 13. (Olivia Aldridge/Community Impact Newspaper)

After six reported cases of a rare and severe blood clot in patients who received the vaccine, the Centers for Disease Control and Prevention and U.S. Food and Drug Administration are recommending a pause on administration of the Johnson & Johnson COVID-19 vaccine.

The six cases occurred six to 13 days after vaccination in women between the ages of 18-48, according to a joint statement from the FDA and CDC.

Dr. Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said in a media conference that one case was fatal, and one patient is in critical condition.

The single-shot Johnson & Johnson vaccine is the least administered nationwide among the three versions of the vaccine available to Americans. According to CDC data, about 6.9 million doses of the Johnson & Johnson vaccine have been administered, accounting for about 3.6% of all doses. There have been no similar complications reported as a result of either the Moderna or Pfizer vaccines.

Dr. Anne Schuchat, principal deputy director of the CDC, said anyone who received the vaccine within about the last two weeks should be aware of symptoms including severe headaches, abdominal pain, leg pain or shortness of breath and contact their health care provider to seek medical treatment if the symptoms occur.


"These symptoms are different from the mild, flu-like symptoms that many people experience in the couple of days after receiving the vaccine," Schuchat said in the call with reporters.

Although the cases are extremely rare—fewer than one in 1 million recipients of the Johnson & Johnson vaccines experienced the blood clot—the CDC and FDA are reviewing the cases during this recommended pause. Dr. Janet Woodcock, acting commissioner of the FDA, told reporters she expects the pause to be "a matter of days."

Marks emphasized the FDA and CDC message to providers is a recommendation and not a mandate, leaving both medical providers and patients to make individual decisions.

"If an individual health care provider has a conversation with an individual patient and they determine that the benefit-risk for that individual patient is appropriate, we’re not going to stop that provider from administering the vaccine," he said.

As of April 13, the Arizona Department of Health Services had administered 4.17 million doses of the COVID-19 vaccine, with more than 2.59 million people having received at least one dose of the vaccine. The total percent of people in Arizona who have received the vaccine is 36%, according to ADHS. The state does not identify the number of doses of the vaccine given to Arizonans by specific companies.